{"nctId":"NCT00598832","briefTitle":"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","startDateStruct":{"date":"2007-11"},"conditions":["Acne Vulgaris"],"count":1075,"armGroups":[{"label":"Adapalene lotion 0.1%","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene lotion 0.1%"]},{"label":"Adapalene Lotion vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Adapalene Lotion Vehicle"]}],"interventions":[{"name":"Adapalene lotion 0.1%","otherNames":[]},{"name":"Adapalene Lotion Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with Moderate or Severe Acne Vulgaris,\n* 20-50 papules and pustules in total on the face excluding the nose\n* 30-100 non-inflammatory lesions on the face excluding the nose.\n* Negative urine pregnancy test for all females.\n\nExclusion Criteria:\n\n* Subjects with more than one acne nodule.\n* Subjects with any acne cyst on the face.\n* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment.\n* Subjects with underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy, such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea.\n* Subjects who are pregnant, nursing, or planning a pregnancy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12","description":"Success defined as percentage of subjects who achieved at least a two-grade reduction in IGA scale (e.g from moderate to clear or almost clear)at week 12 from baseline, Last Observation Carried Forward, Intent to treat population. The IGA (Investigator Global Assessment) is defined as a 5 point scale (0 to 4). \"0\" = clear , \"1\"= almost clear, \"2\"= mild, \"3\"= moderate, \"4\"=severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Lesion Count From Baseline to Week 12","description":"Percent change in lesion count from baseline to week 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.5","spread":"29.6"},{"groupId":"OG001","value":"-37.1","spread":"34.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.9","spread":"31.9"},{"groupId":"OG001","value":"-40.3","spread":"40.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.6","spread":"34.0"},{"groupId":"OG001","value":"-35.7","spread":"38.0"}]}]}]},{"type":"PRIMARY","title":"Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":"1.0"},{"groupId":"OG001","value":"25.5","spread":"1.0"}]}]}]},{"type":"PRIMARY","title":"Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"0.4"},{"groupId":"OG001","value":"10.2","spread":"0.4"}]}]}]},{"type":"PRIMARY","title":"Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":"0.8"},{"groupId":"OG001","value":"15.3","spread":"0.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":533},"commonTop":["Dry skin"]}}}